Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: A Children's Oncology Group phase i study

Neuro-Oncology

Volumn 10, Issue 5, 2008, Pages 752-758

  Bradley, Kristin A ^a   Pollack, Ian F ^b   Reid, Joel M ^c   Adamson, Peter C ^d   Ames, Matthew M ^c   Vezina, Gilbert ^e   Blaney, Susan ^f   Ivy, Percy ^g   Zhou, Tianni ^h   Krailo, Mark ⁱ   Reaman, Gregory ^h   Mehta, Minesh P ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c MAYO CLINIC   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h CHILDREN S ONCOLOGY GROUP   (United States)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Motexafin gadolinium; Pontine glioma; Radiation therapy

Indexed keywords

GADOLINIUM TEXAPHYRIN; METALLOPORPHYRIN; RADIOSENSITIZING AGENT;

ADOLESCENT; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; GLIOMA; HEADACHE; HUMAN; HYPERTENSION; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PONS ANGLE TUMOR; PRESCHOOL CHILD; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SCHOOL CHILD; SIDE EFFECT; TREATMENT OUTCOME; VOMITING; AREA UNDER THE CURVE; BRAIN STEM TUMOR; HALF LIFE TIME; MAXIMUM TOLERATED DOSE; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PONS; RADIOTHERAPY;

ADOLESCENT; ADULT; AREA UNDER CURVE; BRAIN STEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; GLIOMA; HALF-LIFE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MAXIMUM TOLERATED DOSE; METALLOPORPHYRINS; PONS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY;

EID: 56149091530     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-043     Document Type: Article

References (30)

1. Jallo GI, Biser-Rohrbaugh A, Freed D. Brainstem gliomas. Childs Nerv Syst. 2004;20:143-153.
2. Smith MA, Freidlin B, Ries LA, et al. Trends in reported incidence of primary malignant brain tumors in children in the United States. J Natl Cancer Inst. 1998;90:1269-1277.
3. Donaldson SS, Laningham F, Fisher PG. Advances toward an understanding of brainstem gliomas. J Clin Oncol. 2006;24:1266-1272.
4. Albright AL, Guthkelch AN, Packer RJ, et al. Prognostic factors in pediatric brain-stem gliomas. J Neurosurg. 1986;65:751-755.
5. Fisher PG, Breiter SN, Carson BS, et al. A clinicopathologic reappraisal of brain stem tumor classification. Identification of pilocystic astrocytoma and fibrillary astrocytoma as distinct entities. Cancer. 2000;89:1569-1576.
6. Freeman CR, Farmer JP. Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol Phys. 1998;40:265-271.
7. Freeman CR, Krischer JP, Sanford RA, et al. Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study. Int J Radiat Oncol Biol Phys. 1993;27:197-206.
8. Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 2006;7:241-248.
9. Lewis J, Lucraft H, Gholkar A. UKCCSG study of accelerated radiotherapy for pediatric brain stem gliomas. United Kingdom Childhood Cancer Study Group. Int J Radiat Oncol Biol Phys. 1997;38:925-929.
10. Packer RJ, Boyett JM, Zimmerman RA, et al. Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfraction-ated radiotherapy. A Childrens Cancer Group Phase I/II Trial. Cancer. 1994;74:1827-1834.
11. Prados MD, Wara WM, Edwards MS, et al. The treatment of brain stem and thalamic gliomas with 78 Gy of hyperfractionated radiation therapy. Int J Radiat Oncol Biol Phys. 1995;32:85-91.
12. Rubin G, Michowitz S, Horev G, et al. Pediatric brain stem gliomas: an update. Childs Nerv Syst. 1998;14:167-173.
13. Fisher PG, Donaldson SS. Hyperfractionated radiotherapy in the management of diffuse intrinsic brainstem tumors: when is enough enough? Int J Radiat Oncol Biol Phys. 1999;43:947-949.
14. Packer RJ, Allen JC, Goldwein JL, et al. Hyperfractionated radiotherapy for children with brainstem gliomas: a pilot study using 7,200 cGy. Ann Neurol. 1990;27:167-173.
15. Packer RJ, Boyett JM, Zimmerman RA, et al. Hyperfractionated radiation therapy (72 Gy) for children with brain stem gliomas. A Children's Cancer Group Phase I/II Trial. Cancer. 1993;72:1414-1421.
16. Bernier-Chastagner V, Grill J, Doz F, et al. Topotecan as a radiosen-sitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study. Cancer. 2005;104:2792-2797.
17. Doz F, Neuenschwander S, Bouffet E, et al. Carboplatin before and during radiation therapy for the treatment of malignant brain stem tumours: a study by the Société Française d'Oncologie Pédiatrique. Eur J Cancer. 2002;38:815-819.
18. Marcus KJ, Dutton SC, Barnes P, et al. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. Int J Radiat Oncol Biol Phys. 2003;55:1182-1185.
19. Packer RJ, Krailo M, Mehta M, et al. Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas. Cancer. 2005;104:1281-1287.
20. Sanghavi SN, Needle MN, Krailo MD, et al. A phase I study of topote-can as a radiosensitizer for brainstem glioma of childhood: first report of the Children's Cancer Group-0952. Neuro-oncol. 2003;5:8-13.
21. Hashemy SI, Ungerstedt JS, Zahedi Avval F, et al. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J Biol Chem. 2006;281:10691-10697.
22. Carde P, Timmerman R, Mehta MP, et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol. 2001;19:2074-2083.
23. Mehta MP, Shapiro WR, Glantz MJ, et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol. 2002;20:3445-3453.
24. Ramanathan RK, Fakih M, Mani S, et al. Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers. Cancer Chemother Pharmacol. 2006;57:465-474.
25. Miles DR, Smith JA, Phan SC, et al. Population pharmacokinetics of motexafin gadolinium in adults with brain metastases or glioblastoma multiforme. J Clin Pharmacol. 2005;45:299-312.
26. Miller RA, Woodburn K, Fan Q, et al. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int J Radiat Oncol Biol Phys. 1999;45:981-989.
27. Mehta M, Ford JM, Suh J, et al. Cumulative dose of motexafin gadolinium and survival in newly diagnosed glioblastoma multiforme [abstract]. Neuro-oncol. 2004;6:378.
28. Meyers CA, Smith JA, Bezjak A, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol. 2004;22:157-165.
29. Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003;21:2529-2536.
30. Watling CJ, Lee DH, Macdonald DR, et al. Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol. 1994;12:1886-1889.